https://www.selleckchem.com/pr....oducts/pf-06463922.h
Dupilumab, a monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signalling is indicated in dermatology for the treatment of moderate-to-severe atopic dermatitis (AD) in adult and adolescent patients 12 years and older and severe AD in children 6-11 years, who are candidates for systemic therapy. Dupilumab received Early Access to Medicines Scheme (EAMS) approval for adults in March 2017. The purpose of this study was to assess the efficacy outcomes of treatment with dupilumab in EAMS. A retrospect
Aimer
Commentaire
Partagez
